Financial News Feed

Stronger Sell Today ALDX ranks #5721 as SELL CANDIDATE #5721 Weaker Sell

Aldeyra Therapeutics stock forecast

ALDX stock forecast

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd …...

Read more

ALDX earnings call for the period ending ....

Read more

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q1 2019 Earnings Conference Call May 9, 2019 08:00 AM ET Company Participants Todd Brady - Chief Executive Officer Josh...

Read more

Aldeyra Therapeutics misses by $0.16
11:11am, Thursday, 09'th May 2019
Aldeyra Therapeutics (ALDX): Q1 GAAP EPS of -$0.58 misses by $0.16. Cash, cash equivalents, and marketable securities of $82.1M Press Release...

Read more

The following slide deck was published by Aldeyra Therapeutics, Inc. in conjunction with this event....

Read more

Opening Bell, April 30, 2019
01:30pm, Tuesday, 30'th Apr 2019
Ringing today's opening bells are ViiV Healthcare Limited with Dr. John Pottage, senior VP and chief scientific and medical officer, at the NSYE and Aldeyra Therapeutics with President, Director and CEO Dr. Todd Brady at the Nasdaq....

Read more

Today's Bell Ringer, April 30, 2019
01:15pm, Tuesday, 30'th Apr 2019
Today's bell ringers are ViiV Healthcare Limited with Dr. John Pottage, senior VP and chief scientific and medical officer, at the NSYE and Aldeyra Therapeutics with President, Director and CEO Dr. Todd Brady at the Nasdaq....

Read more

Both Radius Health Inc. (NASDAQ:RDUS) and Aldeyra Therapeutics Inc. (NASDAQ:ALDX) are Biotechnology companies, competing one another. We will compare their analyst recommendations, profitability, risk...

Read more

Both Halozyme Therapeutics Inc. (NASDAQ:HALO) and Aldeyra Therapeutics Inc. (NASDAQ:ALDX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regard...

Read more

As Biotechnology businesses, Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), are affected by contrast. This especially applies to their profitability, institutio...

Read more

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and ContraFect Corporation (NASDAQ:CFRX) are two firms in the Biotechnology that compete against each other. Below is a...

Read more

The Earnings to Price yield of Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) is -0.157219. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one...

Read more

Major market players are buzzing over Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) as their share price hit $9.28 at the end of the most recent trading session. Outstanding shares are common stock authori...

Read more

Analysts expect Principal Financial Group, Inc. (NASDAQ:PFG) to report $1.25 EPS on April, 25.They anticipate $0.15 EPS change or 10.71% from last quarter’s $1.4 EPS. PFG’s profit would be $347.90...

Read more

683 Capital Management Llc increased its stake in Aldeyra Therapeutics Inc (ALDX) by 3.24% based on its latest 2018Q4 regulatory filing with the SEC. 683 Capital Management Llc bought 43,700 shares as...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank